Crescent Biopharma grants options for 23,550 shares as inducement awards
Crescent Biopharma granted options for 23,550 shares to two non-executive employees as inducement awards. The options have a 10-year term, an exercise price of $17.57, and vest over time starting from the first anniversary of employment.
*this image is generated using AI for illustrative purposes only.
Crescent Biopharma, Inc. has granted options to purchase an aggregate of 23,550 ordinary shares to two non-executive employees as equity inducement awards. The grants were approved by the independent Compensation Committee of its Board of Directors on June 10, 2026, under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan. These awards were material to each employee's acceptance of employment with the company, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options were granted with a 10-year term and an exercise price equal to $17.57, which was the closing price per share of Crescent's ordinary shares as reported by Nasdaq on June 10, 2026. The vesting schedule for the options is structured to incentivize continued service with the company.
Vesting Schedule
The options granted to each employee vest and become exercisable according to a specific schedule. The table below outlines the vesting terms:
| Vesting Milestone | Portion of Shares | Frequency |
|---|---|---|
| First anniversary of start date | 1/4th | One-time |
| Thereafter | 1/48th | Monthly |
All vesting is subject to the employee's continuous service with Crescent through the applicable vesting dates. The options are also subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.
Crescent Biopharma is a clinical-stage biotechnology company focused on advancing therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs).
How will these equity inducement awards impact Crescent Biopharma's shareholder dilution over the next decade?
What specific expertise do these new non-executive employees bring to advance the PD-1 x VEGF bispecific antibody and ADC pipeline?
Does this hiring signal an acceleration in clinical trial activities for Crescent's lead oncology candidates?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
